Form 4: CFO Exercises Enliven Therapeutics Stock Options

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, exercised 13,000 stock options, acquiring common stock.

Summary

• Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), executed an insider transaction.
• On December 22, 2025, Hohl exercised 13,000 stock options at an exercise price of $2.48 per share.
• This transaction resulted in the acquisition of 13,000 shares of Enliven Therapeutics common stock.
• Following the transaction, Hohl directly beneficially owns 36,000 shares of common stock.
• Hohl also directly beneficially owns 92,056 stock options.
• The exercised options were fully vested and exercisable as of the transaction date.

Sentiment

Score: 7

Explanation: The exercise of stock options by a CFO, leading to an increase in direct common stock ownership, generally indicates confidence in the company's future performance. While a routine transaction, it's a positive signal of insider alignment with shareholder interests.

Positives

• A key executive, the CFO, is increasing direct ownership of company common stock, which can signal confidence in the company's future prospects.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it is a report of an insider transaction.

Management Comments

• All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Industry Context

Insider transactions like option exercises are common in the biotechnology and pharmaceutical industries, where equity compensation is a significant part of executive remuneration. Such transactions are typically viewed as routine but can also signal management's confidence in the company's future prospects, especially when executives increase their direct shareholdings.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May view the CFO's increased direct ownership as a positive signal of management confidence.

Next Steps

• No specific future actions or milestones are mentioned in this insider transaction report.

Key Dates

Recommendation

The filing details a routine insider transaction where the CFO exercised stock options and acquired common stock. This action, while positive as it increases insider ownership, does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It primarily reflects the execution of existing equity compensation plans.

Keywords

Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, Stock Option Exercise, Insider Transaction, Form 4, Beneficial Ownership, Equity Compensation